Société de Therapeutique Marocaine Past Earnings Performance
Past criteria checks 2/6
Société de Therapeutique Marocaine has been growing earnings at an average annual rate of 7.7%, while the Pharmaceuticals industry saw earnings growing at 6.4% annually. Revenues have been growing at an average rate of 9.8% per year. Société de Therapeutique Marocaine's return on equity is 17.4%, and it has net margins of 10.6%.
Key information
7.7%
Earnings growth rate
7.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 9.8% |
| Return on equity | 17.4% |
| Net Margin | 10.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Société de Therapeutique Marocaine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,486 | 263 | 700 | 0 |
| 30 Sep 23 | 2,411 | 262 | 673 | 0 |
| 30 Jun 23 | 2,336 | 260 | 646 | 0 |
| 31 Mar 23 | 2,319 | 264 | 625 | 0 |
| 31 Dec 22 | 2,302 | 267 | 605 | 0 |
| 30 Sep 22 | 2,268 | 286 | 588 | 0 |
| 30 Jun 22 | 2,233 | 306 | 572 | 0 |
| 31 Mar 22 | 2,145 | 293 | 557 | 0 |
| 31 Dec 21 | 2,056 | 279 | 542 | 0 |
| 30 Sep 21 | 1,998 | 264 | 528 | 0 |
| 30 Jun 21 | 1,940 | 249 | 513 | 0 |
| 31 Mar 21 | 1,869 | 240 | 492 | 0 |
| 31 Dec 20 | 1,798 | 230 | 471 | 0 |
| 30 Sep 20 | 1,737 | 233 | 448 | 0 |
| 30 Jun 20 | 1,675 | 235 | 424 | 0 |
| 31 Mar 20 | 1,680 | 227 | 440 | 0 |
| 31 Dec 19 | 1,686 | 220 | 456 | 0 |
| 30 Sep 19 | 1,647 | 173 | 430 | 0 |
| 30 Jun 19 | 1,667 | 196 | 481 | 0 |
| 31 Mar 19 | 1,629 | 207 | 471 | 0 |
| 31 Dec 18 | 1,561 | 182 | 423 | 0 |
| 30 Sep 18 | 1,544 | 208 | 453 | 0 |
| 30 Jun 18 | 1,497 | 198 | 444 | 0 |
| 31 Mar 18 | 1,456 | 174 | 436 | 0 |
| 31 Dec 17 | 1,415 | 150 | 429 | 0 |
| 30 Sep 17 | 1,400 | 153 | 417 | 0 |
| 30 Jun 17 | 1,386 | 155 | 405 | 0 |
| 31 Mar 17 | 1,356 | 152 | 397 | 0 |
| 31 Dec 16 | 1,326 | 149 | 390 | 0 |
| 30 Sep 16 | 1,261 | 135 | 386 | 0 |
| 30 Jun 16 | 1,195 | 121 | 383 | 0 |
| 31 Mar 16 | 1,175 | 119 | 379 | 0 |
| 31 Dec 15 | 1,156 | 118 | 375 | 0 |
| 30 Sep 15 | 1,155 | 115 | 370 | 0 |
| 30 Jun 15 | 1,155 | 113 | 366 | 0 |
| 31 Mar 15 | 1,138 | 102 | 360 | 0 |
| 31 Dec 14 | 1,122 | 92 | 354 | 0 |
| 30 Sep 14 | 1,125 | 95 | 353 | 0 |
| 30 Jun 14 | 1,129 | 97 | 351 | 0 |
| 31 Mar 14 | 1,124 | 107 | 345 | 0 |
| 31 Dec 13 | 1,119 | 117 | 338 | 0 |
| 30 Sep 13 | 1,093 | 118 | 327 | 0 |
| 30 Jun 13 | 1,066 | 118 | 316 | 0 |
Quality Earnings: SOT has high quality earnings.
Growing Profit Margin: SOT's current net profit margins (10.6%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOT's earnings have grown by 7.7% per year over the past 5 years.
Accelerating Growth: SOT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SOT had negative earnings growth (-1.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.4%).
Return on Equity
High ROE: SOT's Return on Equity (17.4%) is considered low.